The Association of ITGBL1 and LPPR4/PRG1 Expression Profile in Patients with Prostate Cancer History
Asmaalsadat Nikkhouy-Tanha, Nazanin Nazari, Maryam Moradi, Mahsa Talebi, Fatima Masoomi Sarvestani, Fatemeh Rahmanzad, Maryam Mahmoudi, Zahra Jafarinia, Banafsheh RastegariBackground:
Prostate cancer is ranked as the most widespread malignancy, among men with the second level of mortality in the United States after lung cancer. Despite the low frequency of prostate cancer incidence in Iran, it has been informed as the fourth most predominant cancer among men with 6% of all deaths from cancer. Recent studies suggest that several hot spot points are indirectly associated with the incidence of prostate neoplasm. Our study aimed to test whether two different ITGBL1 and LPPR4/PRG1 gene expression levels are linked with prostate cancer incidence.
Materials and Methods:
40 prostate tissue biopsies representing confirmed cancer and 41 normal tissues were selected. RNA extraction, cDNA synthesis, and TaqMan Real-time PCR were done according to the standard guidelines.
Results:
Among all 81 biopsy samples that were analyzed, expression levels of ITGBL1 have been significantly elevated in patients with prostate cancer. Also, the results of the present study showed that there was no significant correlation between LPPR4/PRG1 expression levels (2.79 ± 3.83) with prostate cancer incidence, while there has been no association between LPPR4/PRG1 expression levels (1.85 ± 1.55) in a patient with prostate cancer history out of control.
Conclusion:
According to the role of ITGBL1 in several tumor phenotypes, we cannot ignore the importance of ITGBL1 genes as one of the critical regulatory proteins in prostate cancer development or progression. Therefore, more studies are required to explore the associations of prostate cancer with these regulatory proteins in more Iranian populations.